Read the current Defeat Diabetes® E-Lerts™ Newsletter

This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information:
verify here.

 
 
 
     
    
      
       
Defeat Diabetes
Foundation
150 153rd Ave,
Suite 300

Madeira Beach, FL 33708
  

MannKind Inhaled Insulin Matches Injections -Study

Posted: Thursday, September 21, 2006

An inhaled insulin being developed by MannKind Corp produces comparable improvements in blood sugar control to rapid-acting insulin analog (RAA) given by injection, researchers said on Saturday.

The positive Phase III clinical trial results were presented at the annual meeting of the European Association for the Study of Diabetes.

MannKind Chief Scientific Officer Peter Richardson added that no adverse effect on pulmonary function was observed with the Californian company's Technosphere Insulin system, reassuring investigators that it does not harm the lungs.

Encouragingly, given the link between diabetes and obesity, Technosphere Insulin patients lost weight during the treatment period, unlike those given injections.

The 24-week study included 308 patients with Type 2 diabetes.

MannKind is one of several companies racing to develop inhaled forms of insulin, which are more convenient than the normal practice of injections.

The market leader is Pfizer Inc, whose Exubera product, which uses an inhaler developed by Nektar Therapeutics, has already been launched in major markets.

Presented at the annual meeting of the European Association for the Study of Diabetes. (EASD)

 

Source: Diabetes In Control

 
 
 
 
 
Join us on Facebook
 
 
 

Send your unopened, unexpired diabetes testing supplies to:

Defeat Diabetes Foundation
150 153rd Ave, Suite 300
Madeira Beach, FL 33708

 

DDF advertisement
 

 Friendly Banner
 


Friendly Banner
 
 
 
Analyze nutrition content by portion
DDF advertisement